相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Counter-regulatory renin-angiotensin system in cardiovascular disease
Maria Paz Ocaranza et al.
NATURE REVIEWS CARDIOLOGY (2020)
Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects
Julliane V. Joviano-Santos et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2020)
The global epidemiology of hypertension
Katherine T. Mills et al.
NATURE REVIEWS NEPHROLOGY (2020)
Combinatorial inhibition of Angiotensin converting enzyme, Neutral endopeptidase and Aminopeptidase N by N-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension
Mysuru Natarajan Savitha et al.
PEPTIDES (2020)
B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction
Takafumi Minato et al.
NATURE COMMUNICATIONS (2020)
Angiotensin-[1-7] attenuates kidney injury in experimental Alport syndrome
Hong Sang Choi et al.
SCIENTIFIC REPORTS (2020)
Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage
Raffaele Altara et al.
HYPERTENSION (2020)
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease
Daniel P. Zimmer et al.
FRONTIERS IN PHARMACOLOGY (2020)
Cardiac natriuretic peptides
Jens P. Goetze et al.
NATURE REVIEWS CARDIOLOGY (2020)
Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19
John A. Jarcho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure
Courtney M. Shea et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)
Angiotensin converting enzyme-2 as therapeutic target in COVID-19
Neda Roshanravan et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide
Tomoko Ichiki et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats
Giovanna Castoldi et al.
ACTA DIABETOLOGICA (2019)
Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice
Solene Emmanuelle Boitard et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Anti-fibrotic mechanisms of angiotensin AT2-receptor stimulation
Colin Sumners et al.
ACTA PHYSIOLOGICA (2019)
Cardiorenal Syndrome Pathophysiology
Ujjala Kumar et al.
CARDIOLOGY CLINICS (2019)
CRRL269 A Novel Particulate Guanylyl Cyclase A Receptor Peptide Activator for Acute Kidney Injury
Yang Chen et al.
CIRCULATION RESEARCH (2019)
Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions
Mathilde Keck et al.
CURRENT HYPERTENSION REPORTS (2019)
Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
Sadayoshi Ito et al.
JOURNAL OF HUMAN HYPERTENSION (2019)
C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts
Yang Chen et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH
Katherine C. Hall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins A Phase 2, Open-Label, Multicenter, Dose-Titrating Study
Keith C. Ferdinand et al.
CIRCULATION (2019)
Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen
Estrellita Uijl et al.
HYPERTENSION (2019)
NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension
Mathilde Keck et al.
HYPERTENSION (2019)
Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis
Yongmei Cao et al.
LABORATORY INVESTIGATION (2019)
Abstract 131: Insulin Regulated Aminopeptidase Inhibitors are More Effective Than the ACE Inhibitor, Perindopril in Preventing Unilateral Ureteral Obstruction-Induced Renal Fibrosis in Mice
Sharenya Chelvaretnam et al.
HYPERTENSION (2019)
Stimulation of the ACE2/Ang-(1-7)/Mas axis in hypertensive pregnant rats attenuates cardiovascular dysfunction in adult male offspring
Amanda S. M. Bessa et al.
HYPERTENSION RESEARCH (2019)
Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
Hiromi Rakugi et al.
HYPERTENSION RESEARCH (2019)
Structural insights into the mechanism of human soluble guanylate cyclase
Yunlu Kang et al.
NATURE (2019)
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Lauren B. Arendse et al.
PHARMACOLOGICAL REVIEWS (2019)
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
Daniel Lavall et al.
BIOCHEMICAL PHARMACOLOGY (2019)
P6342Subcutaneous delivery of NPA7, first-in-class novel bispecific designer peptide: enhances cardiorenal function and suppresses renin and aldosterone in vivo and in vitro
S Sugihara et al.
EUROPEAN HEART JOURNAL (2019)
Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease
Akira Nishiyama
HYPERTENSION RESEARCH (2019)
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
Lei Li et al.
HYPERTENSION RESEARCH (2019)
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction
Frans H. H. Leenen et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2019)
Myocardial hypertrophy induced by high salt consumption is prevented by angiotensin II AT2 receptor agonist
E. P. B. Dopona et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)
Angiotensin-(1-7) inhibits sodium transport via Mas receptor by increasing nitric oxide production in thick ascending limb
Paula Dibo et al.
PHYSIOLOGICAL REPORTS (2019)
Nebivolol prevents vascular oxidative stress and hypertension in rats chronically treated with ethanol
Gabriel T. do Vale et al.
ATHEROSCLEROSIS (2018)
Dimerization of AT2 and Mas Receptors in Control of Blood Pressure
Sanket Patel et al.
CURRENT HYPERTENSION REPORTS (2018)
Angiotensin-converting enzyme 2 and renal disease
Vanessa R. Williams et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2018)
The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective
Shalini M. Krishnan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease
Yasunori Suematsu et al.
JOURNAL OF CARDIAC FAILURE (2018)
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease
Jenny Tobin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
Krister Bamberg et al.
PLOS ONE (2018)
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Philipp Schwabl et al.
SCIENTIFIC REPORTS (2018)
The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury
Anandharajan Rathinasabapathy et al.
FRONTIERS IN PHYSIOLOGY (2018)
Hypertension
Suzanne Oparil et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats
Carmen Castardeli et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
COMPARING ANTI-FIBROTIC EFFECTS OF THE IRAP INHIBITOR, HFI-419 TO AN ANGIOTENSIN RECEPTOR BLOCKER AND ACE INHIBITOR IN A HIGH SALT-INDUCED MOUSE MODEL OF KIDNEY DISEASE
Tracey Gaspari et al.
JOURNAL OF HYPERTENSION (2018)
Recent Advances in Angiotensin Research
Katrina M. Mirabito Colafella et al.
HYPERTENSION (2017)
Deletion of Angiotensin-Converting Enzyme-2 Promotes Hypertensive Nephropathy by Targeting Smad7 for Ubiquitin Degradation
Zhen Liu et al.
HYPERTENSION (2017)
Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage
A. Coats et al.
JOURNAL OF HUMAN HYPERTENSION (2017)
NPA7, A FIRST IN CLASS DUAL RECEPTOR ACTIVATOR WITH CARDIO-RENOPROTECTIVE PROPERTIES IN VIVO
Laura Meems et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
Peter Sandner et al.
RESPIRATORY MEDICINE (2017)
The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer
Juanjuan Xu et al.
FRONTIERS IN PHYSIOLOGY (2017)
Therapeutic impact of dietary vitamin D supplementation for preventing right ventricular remodeling and improving survival in pulmonary hypertension
Hiroaki Tanaka et al.
PLOS ONE (2017)
Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition
Yukiko Kato et al.
SCIENTIFIC REPORTS (2017)
Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
Vajir Malek et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Global Disparities of Hypertension Prevalence and Control A Systematic Analysis of Population-Based Studies From 90 Countries
Katherine T. Mills et al.
CIRCULATION (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
Shigehiro Katayama et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats
Kiyoshi Arai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Activation of angiotensin II type 2 receptor suppresses TNF-α-induced ICAM-1 via NF-κB: possible role of ACE2
Liping Zhu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Hypertension Renin-Angiotensin-Aldosterone System Alterations
Luuk te Riet et al.
CIRCULATION RESEARCH (2015)
New Approaches in the Treatment of Hypertension
Suzanne Oparil et al.
CIRCULATION RESEARCH (2015)
Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
Johannes-Peter Stasch et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
Stephan Rosenkranz et al.
HEART (2015)
The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure
Eugene Braunwald
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Novel RAAS agonists and antagonists: clinical applications and controversies
CesarA. Romero et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Neprilysin inhibition in chronic kidney disease
Parminder Judge et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
Linda S. Hoffmann et al.
PLOS ONE (2015)
AT2 Receptor Activation Induces Natriuresis and Lowers Blood Pressure
Brandon A. Kemp et al.
CIRCULATION RESEARCH (2014)
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets
Fan Jiang et al.
NATURE REVIEWS CARDIOLOGY (2014)
Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol
Shereen M. Hamza et al.
FRONTIERS IN PHYSIOLOGY (2014)
444 AT4 RECEPTOR/INSULIN REGULATED AMINOPEPTIDASE DEFICIENCY IS BOTH VASO- AND CARDIO-PROTECTIVE UNDER CONDITION OF CARDIOVASCULAR STRESS IN MICE
T.A. Gaspari et al.
JOURNAL OF HYPERTENSION (2012)
CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
Fernando L. Martin et al.
PLOS ONE (2012)
Acute superoxide scavenging restores depressed baroreflex sensitivity in renovascular hypertensive rats
Mayumi S. Botelho-Ono et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2011)
Emerging drugs which target the renin-angiotensin-aldosterone system
Ulrike Muscha Steckelings et al.
EXPERT OPINION ON EMERGING DRUGS (2011)
Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure-Independent Manner
Philipp Kalk et al.
HYPERTENSION (2011)
A Single β-Amino Acid Substitution to Angiotensin II Confers AT2 Receptor Selectivity and Vascular Function
Emma S. Jones et al.
HYPERTENSION (2011)
Linking Oxidative Stress, the Renin-Angiotensin System, and Hypertension
Camilla Fanelli et al.
HYPERTENSION (2011)
Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting
Akira Sezai et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy
Gavin Y. Oudit et al.
DIABETES (2010)
Intrarenal Aminopeptidase N Inhibition Restores Defective Angiontesin II Type 2-Mediated Natriuresis in Spontaneously Hypertensive Rats
Shetal H. Padia et al.
HYPERTENSION (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination
Andrew S. Bomback et al.
AMERICAN JOURNAL OF HYPERTENSION (2009)
Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage
Paolo Gelosa et al.
JOURNAL OF HYPERTENSION (2009)
Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice
Ralf A. Benndorf et al.
KIDNEY INTERNATIONAL (2009)
Angiotensin II Type 2 Receptor Stimulation A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?
Elena Kaschina et al.
CIRCULATION (2008)
Orally active aminopeptidase A inhibitors reduce blood pressure -: A new strategy for treating hypertension
Laurence Bodineau et al.
HYPERTENSION (2008)
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Puja K. Mehta et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase
Carmine Savoia et al.
JOURNAL OF HYPERTENSION (2006)
Vasoconstrictive effect of angiotensin IV in isolated rat basilar artery independent of AT(1) and AT(2) receptors
S Faure et al.
JOURNAL OF VASCULAR RESEARCH (2006)
Dietary NaCl regulates renal aminopeptidase N: Relevance to hypertension in the Dahl rat
M Farjah et al.
HYPERTENSION (2004)
Recent clinical trials with omapatrilat: New developments
A Zanchi et al.
CURRENT HYPERTENSION REPORTS (2003)
AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium
G Wiemer et al.
HYPERTENSION (2002)
Angiotensin-converting enzyme 2 is an essential regulator of heart function
MA Crackower et al.
NATURE (2002)
Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase
AL Albiston et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release
SF Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2000)
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
UP Jorde et al.
CIRCULATION (2000)
分享论文
